Funding for this research was provided by:
Arthritis New Zealand (R260)
Text and Data Mining valid from 2019-03-14
Received: 29 November 2018
Accepted: 6 March 2019
First Online: 14 March 2019
Ethics approval and consent to participate
: This research was completed under the ethical approval of Health Disability Ethics Committee (HDEC 17/NTB/3) New Zealand.
: Not applicable.
: PT, TM and AW do not have any conflicts or competing interests to declare. KR has received funding from ASICS, outside the submitted work. Prof Dalbeth reports research grant funding from Amgen and AstraZeneca, and speaker fees from Pfizer Inc., Horizon, Janssen Pharmaceuticals, and AbbVie, as well as consulting fees from Horizon, Hengrui, and Kowa, outside the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.